Knockdown of TRIM24 suppresses growth and induces apoptosis in acute myeloid leukemia through downregulation of Wnt/GSK-3β/β-catenin signaling.

Human & Experimental Toxicology
C LiJ Mu

Abstract

Tripartite motif-containing protein 24 (TRIM24) has currently emerged as a crucial cancer-related gene present in a wide range of human cancer types. However, the involvement of TRIM24 in acute myeloid leukemia (AML) has not been well investigated. The present study aims to investigate the significance, cellular function, and potential regulatory mechanism of TRIM24 in AML. We found that TRIM24 expression was significantly upregulated in AML compared with normal tissues. AML patients with low expression of TRIM24 had higher survival rates than those expressing TRIM24 at higher levels. High expression of TRIM24 was also detected in AML cells and its knockdown markedly restricted proliferation and promoted apoptosis in AML cells. Further investigation revealed that TRIM24 contributed to the regulation of Wnt/β-catenin signaling, which was associated with modulating the phosphorylation status of glycogen synthase kinase-3β (GSK-3β). Inactivation of GSK-3β partially reversed the TRIM24 knockdown-mediated antitumor effects observed in AML cells. Furthermore, knockdown of TRIM24 retarded the growth of AML-derived xenograft tumors in nude mice in vivo. Overall, these findings demonstrate that knockdown of TRIM24 impedes the AML tumor ...Continue Reading

References

Nov 21, 2007·Nature Genetics·Konstantin KhetchoumianRégine Losson
Jun 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Kendra AlltonMichelle Craig Barton
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Dec 24, 2009·Nature Reviews. Cancer·Jianjun ChenJanet D Rowley
Dec 18, 2010·Nature·Wen-Wei TsaiMichelle Craig Barton
Mar 26, 2011·The American Journal of Pathology·Monique ChambonVincent Cavaillès
May 3, 2011·Proceedings of the National Academy of Sciences of the United States of America·Benjamin HerquelRégine Losson
Aug 18, 2012·Leukemia & Lymphoma·Vanessa S SilveiraLuiz Gonzaga Tone
Dec 22, 2012·Nature Reviews. Cancer·Jamie N Anastas, Randall T Moon
Mar 1, 2015·Virchows Archiv : an International Journal of Pathology·Zhi-Feng MiaoHui-Mian Xu
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
May 31, 2016·Cancer Cell·Anna C GronerMyles Brown
Sep 10, 2016·Cell Cycle·Anna C GronerJean-Philippe Theurillat
Oct 23, 2016·Drug Discovery Today. Technologies·Srikanth AppikondaMichelle Craig Barton
Jan 8, 2017·Journal of Hematology & Oncology·Yu-Chan ChangMichael Hsiao
Jan 25, 2017·Journal of Experimental & Clinical Cancer Research : CR·Ziling FangJianping Xiong
Nov 14, 2017·Nature Communications·Deguan LvHaizhong Feng
Feb 2, 2018·Progress in Molecular Biology and Translational Science·Stephanie GraingerKarl Willert
Mar 7, 2018·Nature Chemical Biology·Lara N GechijianJames E Bradner
Apr 9, 2018·Experimental Cell Research·Yefan ZhuBicheng Chen
Jun 11, 2019·Urologic Oncology·Anne OffermannSven Perner

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
PCR
electrophoresis
ELISA
flow cytometry
Assay

Software Mentioned

GraphPad
GraphPad Prism
Pro Plus
PrognoScan
Image

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.